RT Journal Article
T1 Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain.
A1 Requena, S
A1 Lozano, A B
A1 Caballero, E
A1 García, F
A1 Nieto, M C
A1 Téllez, R
A1 Fernández, J M
A1 Trigo, M
A1 Rodríguez-Avial, I
A1 Martín-Carbonero, L
A1 Miralles, P
A1 Soriano, V
A1 de Mendoza, C
A1 HIV-2 Spanish Study Group, 
AB HIV-2 is a neglected virus despite estimates of 1-2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. In this retrospective observational study, we analysed all HIV-2-infected individuals treated with integrase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modalities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126 cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individuals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.
YR 2019
FD 2019
LK http://hdl.handle.net/10668/13555
UL http://hdl.handle.net/10668/13555
LA en
DS RISalud
RD Apr 16, 2025